Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer
Sponsor: Genentech, Inc.
Summary
The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-1261 in participants with advanced or metastatic prostate cancer. It's also to identify a recommended dose(s) and regimen for GDC-1261 for subsequent studies.
Official title: A Phase I/II Dose-escalation and Expansion Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Patients With Advanced or Metastatic Prostate Cancer
Key Details
Gender
MALE
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
260
Start Date
2026-04-29
Completion Date
2027-12-30
Last Updated
2026-06-11
Healthy Volunteers
No
Interventions
GDC-1261
Participants will receive GDC-1261 as per the schedule described in the protocol.
Locations (2)
Honor Health Research Institute
Scottsdale, Arizona, United States
Sarah Cannon Research Institute
Nashville, Tennessee, United States